NCT06203821View on ClinicalTrials.gov

Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Pancreatic Cancer

Interventions

DRUG

NP137

NP137 for the Treatment of Resectable Pancreatic Cancer

Trial Locations (1)

14642

University of Rochester, Rochester

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

NETRIS Pharma

INDUSTRY

lead

Aram Hezel

OTHER

NCT06203821 - Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter